Quinolone is a major class of antibacterial drug. Quinolones or fluoroquinolones are synthetic antibacterial drugs that show a specific function of inhibiting the nucleic acid synthesis. Depending on their bactericidal properties, quinolones are efficient against bacterial infections of the sinuses, lungs, skin, stomach, and urinary tract.
These drugs can interfere with the human DNA synthesis, as humans have the same basic nucleic acid constituents as those of the bacteria. Quinolones exhibit rapid bactericidal activity, wherein they easily infiltrate the bacterial cell membrane and reach the DNA where they bind to bacterial topoisomerases such as DNA gyrase, thus inhibiting the bacterial nucleic acid synthesis. The most extensively used quinolones are norfloxacin and ciprofloxacin Other crucial quinolones include ofloxacin, enoxacin, lomefloxacin, levofloxacin, trovafloxacin, and gatifloxacin.
๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐๐ฒ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ :
- Bayer AG
- Novartis AG.
- Sanofi
- Johnson & Johnson
- Merck & Co, Inc.
- LG Life Sciences
- Allergan, Inc.
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/request-toc-and-sample/15195
๐๐๐ญ ๐๐ฉ ๐๐จ ๐๐% ๐๐ข๐ฌ๐๐จ๐ฎ๐ง๐ญ, ๐๐ข๐ฅ๐ฅ ๐ญ๐ก๐ ๐๐๐ญ๐ ๐๐๐ญ๐ก ๐จ๐ ๐๐ฎ๐ ๐ฎ๐ฌ๐ญ ๐๐๐๐.
๐๐ผ๐๐ถ๐ฑ-๐ญ๐ต ๐ฆ๐ฐ๐ฒ๐ป๐ฎ๐ฟ๐ถ๐ผ:
The COVID-19 virus outbreak in December 2019, the World Health Organization announced it a public health emergency. The disease has spread to over 100 countries and affected huge losses of lives around the globe.
Particularly the global manufacturing, pharmaceutical, tourism, and financial markets have been hit hard. The outbreak of the pandemic has added risk factors to the already weak growth of the world economy. The descending pressure on the world economy that once showed signs of improvement in the previous period has improved again.
The negative global impacts of the COVID-19 are already there, substantially affecting the quinolone market in the coming years, and this factor is expected to have a significantly negative impact on the revenue growth of this industry.
๐
๐จ๐ซ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ง๐ช๐ฎ๐ข๐ซ๐ฒ https://www.alliedmarketresearch.com/purchase-enquiry/15195
In January 2018, Melinta Therapeutics, Inc. introduced Baxdela (delafloxacin), which is an oral fluoroquinolone used to treat adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. The launch of Baxdela offers new treatment option and companyโs growth in the infection therapeutics area.
In September 2019, KYORIN Holdings, Inc. acknowledged an approval from the Japanโs Ministry of Health, Labour and Welfare for the drug Lasvic (lascufloxacin hydrochloride), which is a novel quinolone antibacterial drug specified as a first-line monotherapy to treat community-acquired respiratory and ENT infections. The approval of Lasvic is important milestone for the company to address the growing threat of antimicrobial resistance and provide effective treatment options for patients.
๐๐๐ ๐
๐๐๐๐๐๐๐ ๐๐
๐๐๐ ๐๐๐๐๐
- This study presents the analytical depiction of the quinolones industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the quinolones market share.
- The current market is quantitatively analyzed from 2020 to 2030 to highlight the market growth scenario.
- Porterโs five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
๐๐ญ๐ก๐๐ซ ๐๐ซ๐๐ง๐๐ข๐ง๐ ๐๐๐ฉ๐จ๐ซ๐ญ๐ฌ:
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โMarket Research Reportsโ and โBusiness Intelligence Solutions.โ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com